SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff and sharp, volatile rebound have put traders focus on leveraged liquidations and whether the decline marked a capitulation low. The community is split between buyers calling for a bottom and short squeeze, and bears warning that the bounce may be temporary and further losses could follow.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 471,438,169.1160568 with 446,436,169.1160568 in circulation. The last known price of Avalanche is 6.99518175 USD and is down -15.00 over the last 24 hours. It is currently trading on 1135 active market(s) with $402,139,637.32 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

AVAX is drawing attention amid a sharp crypto-wide selloff, with traders saying Bitcoin weakness is dragging altcoins lower and that AVAX has been falling harder and recovering poorly. The reaction is mostly bearish, though some holders are treating the dip as a buying opportunity.

Bittensor (TAO) is a cryptocurrency launched in 2021and operates on the Bittensor platform. Bittensor has a current supply of 21,000,000 with 11,727,911.30015715 in circulation. The last known price of Bittensor is 182.74993229 USD and is down -15.42 over the last 24 hours. It is currently trading on 339 active market(s) with $220,769,283.80 traded over the last 24 hours. More information can be found at https://bittensor.com.

Bittensor

TAOs steep pullback amid broader crypto selling is driving discussion, with traders debating whether the weakness is a buying opportunity or a sign of more downside. Long-term bulls point to Bittensors decentralized-AI vision, while cautious voices cite macro pressure and the need for stronger proof of subnet adoption and sustainable revenue.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,218,624.4003947. The last known price of Ethereum is 1,739.90377069 USD and is down -9.84 over the last 24 hours. It is currently trading on 14359 active market(s) with $18,820,901,710.98 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp, broad-based crypto selloff, with traders citing Bitcoin weakness and leveraged liquidations; some speculate that macro risk and demand for the anticipated Anthropic IPO are adding pressure. The community is split between calling capitulation and buying the dip versus warning of further losses.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,752,062,860.16806072. The last known price of Dogecoin is 0.05689686 USD and is down -11.89 over the last 24 hours. It is currently trading on 1545 active market(s) with $1,128,721,930.78 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a sharp downturn across crypto, with traders pointing to continued declines and multi-year lows. The community is split between buying the dip and warning of further losses, with skeptics also questioning the coins utility.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyvernas completed BLA submission for miv-cel in stiff person syndrome, with a request for priority review, is driving attention as traders await FDA acceptance and a review timeline. Bulls view the filing and clinical data as a key step toward a potential first autoimmune CAR-T approval, while skeptics point to unresolved safety questions, funding needs and the stocks weak price action.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkors quarterly results and below-consensus next-quarter outlook are driving attention, with traders debating whether the guidance and heavy investment needs outweigh improving margins and AI-related packaging demand. Some view the rebound after a steep selloff as a value opportunity or possible short-covering, while others see it as a temporary bounce amid weaker communications and consumer demand.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile broad-market moves and the Dows relative strength versus technology-heavy indexes, with traders debating whether the market is rotating into Dow components or facing further weakness. Bearish concerns focus on rising Treasury yields, inflation and Iran-related oil risks, while bullish traders see pullbacks as buying opportunities and expect a recovery.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,311,726,877. The last known price of NEAR Protocol is 3.02737751 USD and is down -12.22 over the last 24 hours. It is currently trading on 689 active market(s) with $848,656,832.66 traded over the last 24 hours. More information can be found at https://near.org/.

Near

NEAR is drawing attention amid a sharp selloff and weakness across altcoins, with traders focused on whether the decline is a buying opportunity or signals more downside. Some are adding to positions, while others point to broken support and expect further losses.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos post-earnings surge is drawing attention after faster daily-user growth, revenue and bookings beats, and an improved full-year outlook outweighed an EPS miss. Bulls see the results as evidence that AI is supporting engagement rather than displacing the app, while skeptics question monetization, margins, valuation, and whether the rally can hold.

statis crypto Watchlist

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...

EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -21.59% and +278.00%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is...

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ --Pomerantz LLP is...

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPR NewswireNEW YORK, Oct. 20, 2026 EyePoint...

Why AZN, VSXY, EYPT Stocks Are Moving Premarket Today

Equity

A healthcare AI collaboration and a bullish retail outlook lift sentiment, while a Phase 3 trial setback puts EyePoint under pressure.

Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today? 

Investors grew wary of the companies’ ability to execute their business plans and manage their finances.


Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.read more...

$EYPT Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$1.07 down -25.88% YoY
• Reported revenue of $0.76M down -21.65% YoY
• EyePoint expects $118M in September 30, 2026 cash, cash equivalents and marketable securities, plus $10M raised subsequent to quarter-end and operational adjustments, to fund operations into late third quarter of 2027.

Stocktwits

EyePoint Pharmaceuticals Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.07 down -25.88% YoY
• Reported revenue of $0.76M down -21.65% YoY
• EyePoint expects $118M in September 30, 2026 cash, cash equivalents and marketable securities, plus $10M raised subsequent to quarter-end and operational adjustments, to fund operations into late third quarter of 2027.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$1.07 down -25.88% YoY
• Reported revenue of $0.76M down -21.65% YoY
• EyePoint expects $118M in September 30, 2026 cash, cash equivalents and marketable securities, plus $10M raised subsequent to quarter-end and operational adjustments, to fund operations into late third quarter of 2027.

EyePoint's wet AMD Phase 3 trials did not achieve their primary endpoints; cash and investments were $118M, and strategic prioritization includes an approximately 53% workforce reduction.

EyePoint's VERONA trial reported +7.1-letter BCVA improvement and 73% supplement-free patients; DME pivotal trials enrolled over 550 patients, while DURAVYU achieved a 42% treatment-burden reduction in LUGANO.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>AstraZeneca shares rise premarket after it agreed to explore AI-driven tools with Oracle to help identify clinical trial candidates and speed up research.</li><li>Barclays raised its VSXY price target and maintained an ‘Overweight’ rating ahead of the retailer’s Q3 report.</li><li>EyePoint Pharmaceuticals shares fell after JPMorgan downgraded the stock to ‘Underweight.’</li></ul><p>Shares of AstraZeneca (AZN), Victoria’s Secret (VSXY) and EyePoint Pharmaceuticals (EYPT) moved in different directions in premarket trading on Tuesday. The moves followed a healthcare AI collaboration, an analyst price-target hike, and a downgrade after a clinical-trial setback.</p><p>AZN shares moved higher after Oracle Corp. (ORCL) announced an agreement to explore AI applications in clinical research. Similarly, VSXY gained after Barclays raised its price target, while EYPT fell after JPMorgan downgraded it.</p><h2 class="st-heading-2">AZN, ORCL Explore AI In Clinical Trials</h2><p><a href="https://stocktwits.com/symbol/AZN">AstraZeneca (AZN) shares</a> gained over 1.8% in premarket trading after Oracle announced a non-binding agreement with the company to explore how artificial intelligence and real-world data could help identify eligible clinical trial participants, speed up research and bring findings into everyday patient care.</p><p>The proposed collaboration would combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s healthcare data, cloud infrastructure, AI, analytics and clinical workflow capabilities. The companies plan to explore tools that could help care teams identify suitable patients earlier, improve clinical trial efficiency and address patient recruitment challenges.</p><h2 class="st-heading-2">Barclays Raises VSXY Price Target</h2><p><a href="https://stocktwits.com/symbol/VSXY">Victoria’s Secret (VSXY) shares</a> gained nearly 1% in premarket trading after Barclays raised its price target to $112 from $106 while maintaining an ‘Overweight’ rating.</p><p>The firm remains constructive on the stock ahead of the company’s third-quarter report. According to the research note, transaction and traffic data point to continued momentum across the business.</p><h2 class="st-heading-2">EYPT Slides After JPMorgan Downgrade</h2><p><a href="https://stocktwits.com/symbol/EYPT">EyePoint Pharmaceuticals (EYPT) shares</a> fell nearly 4.4% after JPMorgan downgraded the stock to ‘Underweight’ from ‘Neutral.’ The firm did not provide a price target.</p><p>The downgrade followed EyePoint’s first Phase 3 trial of Duravyu for wet age-related macular degeneration, which failed to meet its primary endpoint. JPMorgan expects the shares to remain under pressure in the medium term.</p><h2 class="st-heading-2">AZN, VSXY, EYPT Stocks: Stocktwits Retail Sentiment</h2><p>Retail sentiment toward AstraZeneca was ‘neutral,’ unchanged in the past 24 hours, while message volume rose to ‘high’ from ‘normal’ during the same period.&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN shares</a> have fallen around 11% year-to-date.</p><p>Retail sentiment for Victoria’s Secret was ‘bullish,’ while message volume was ‘high,’ both unchanged over the past 24 hours.&nbsp;<a href="https://stocktwits.com/symbol/VSXY">VSXY stock</a> has gained over 193% since the beginning of this year.</p><p>For EyePoint Pharmaceuticals, the sentiment improved to ‘bullish’ from ‘bearish’ in the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ during the same period.&nbsp;<a href="https://stocktwits.com/symbol/EYPT">EYPT stock</a> has declined over 96% year-to-date.&nbsp;</p><p><strong>Also See:</strong>&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-nasdaq-futures-falling-premarket-crwv-nbis-tsla-spcx-mu-asts-nflx-sls-stocks-in-focus/cZxq8CeRBu1">Why Are Nasdaq Futures Falling Premarket? CRWV, NBIS, TSLA, SPCX, MU, ASTS, NFLX, SLS Stocks In Focus</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca PLC

Victoria`s Secret & Co

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

EYPT News